ArticlePloS one2026
Integration of transplanted chemically induced liver progenitor cells into recipient bile ducts in a rat bile duct transection model.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemically induced liver progenitor cells (CLiPs) generated from mature hepatocytes are bipotent and represent a promising source for biliary repair. However, their therapeutic potential in cholangiopathy models remains unclear. In this study, we investigated rat CLiPs using a rat bile duct transection (BDT) model.
methodsRat CLiPs were induced using the Y-27632/A-83-01/CHIR99021 regimen, resulting in loss of the hepatocyte marker ALB and gain of the progenitor markers CD90 and EpCAM. GFP-labeled CLiPs (1 × 10^7) were transplanted into Sprague-Dawley rats following BDT via portal vein infusion. On postoperative days (POD) 3 and 7, engraftment, proliferation, differentiation, and injury indices were assessed using immunofluorescence, quantitative reverse-transcription polymerase chain reaction (qRT-PCR), and serum biochemistry.
resultsCLiPs engrafted and survived until POD 7 after portal vein infusion, and proliferative activity was observed by Ki-67 staining. Immunofluorescence revealed GFP + /ALB+ hepatocyte-like cells and GFP + /CK7 + cholangiocyte-like cells integrating near native ducts, indicating bipotential differentiation. qRT-PCR showed that BDT-induced expression of progenitor/ductular markers (Sox9, Epcam, Krt7, and Krt19) was attenuated in CLiP-treated groups compared to untreated BDT rats, although levels remained above those in sham rats. Serum AST, ALT, and ALP levels tended to decrease, and albumin levels increased after CLiP transplantation.
conclusionsCLiPs survived and acquired hepatocyte-like and cholangiocyte-like phenotypes during the early phase after portal vein transplantation in a rat BDT model. These findings support the feasibility of CLiP-based hepatobiliary regenerative therapy, although longer-term and functional studies are required to confirm durable biliary repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.